TFF PHARMACEUTICALS INC (TFFP)

TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023

TFFP stock results show that TFF Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips TFF Pharmaceuticals (NASDAQ:TFFP) just reported results for the fourth quarter ...

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical...

TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs

Eight of Eight Patients Successfully Transitioned from Oral Tacrolimus to TFF TAC with No Sign of Acute Rejection at Reduced Systemic Exposures Data from...

TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation

Oral Presentation to Present Updated Data from Phase 2 Trial Demonstrating Successful Transition of Patients from Oral Tacrolimus to TFF TAC...

TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

FORT WORTH, Texas, March 22, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage...

TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

FORT WORTH, March 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage...

TFF Pharmaceuticals Announces Update on Clinical Programs

Company to Prioritize Clinical Development of Tacrolimus Inhalation Powder (TFF TAC) based on Positive Phase 2 Data, the Potential to Address a Significant...

TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024

FORT WORTH, Texas, March 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that Harlan Weisman, M.D., Chief Executive Officer of TFF Pharmaceuticals will be presenting a corporate overview at the 36th Annual Roth Conference being held March 17-19, 2024 in Dana Point, California. Company management will also be participating in one-on-one meetings.

TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference

FORT WORTH, Texas, Jan. 24, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on...

TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Misses Revenue for Q1 2023

TFFP stock results show that TFF Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2023.

TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Misses Revenue for Q1 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips TFF Pharmaceuticals (NASDAQ:TFFP) just reported results for the first quarter o...

TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2023

TFFP stock results show that TFF Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2023.

TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips TFF Pharmaceuticals (NASDAQ:TFFP) just reported results for the second quarter ...

TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q3 2023

TFFP stock results show that TFF Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023.

TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q3 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips TFF Pharmaceuticals (NASDAQ:TFFP) just reported results for the third quarter o...

Top Buys by Top Brass: CEO Weisman's $150K Bet on TFFP

TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC

Treatment with TFF VORI resulted in positive treatment outcomes based on clinical, mycologic and radiologic responses while maintaining a favorable...

TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TAC

Company to host conference call and webcast on Tuesday, December 19th at 8:30 am ET...

TFF Pharmaceuticals announces 1-for-25 reverse stock split (NASDAQ:TFFP)

TFF Pharmaceuticals (TFFP) announces a reverse stock split, reducing the number of shares and maintaining trading on the Nasdaq under the symbol TFFP.

TFF Pharmaceuticals Announces Reverse Stock Split

Common Stock Will Begin Trading on a Split-Adjusted Basis on December 19, 2023...

TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors

FORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on...

TFF Pharmaceuticals Appoints Catherine Lee, J.D. to Board of Directors

FORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on...

TFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference – December 7, 2023

FORT WORTH, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on...

TFF Pharmaceuticals files for $100M mixed shelf (NASDAQ:TFFP)

TFF Pharmaceuticals files a $100M shelf offering prospectus, signaling potential financial moves.

TFF Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Company remains on track to report initial data from TFF VORI and TFF TAC Phase 2 trials by the end of 2023 Conference call and webcast, today Tuesday...

TFF Pharmaceuticals to Hold Third Quarter 2023 Financial and Business Results Conference Call on November 14, 2023

Company to hold conference call and webcast on November 14, 2023, at 4:30 PM ET...

TFF Pharmaceuticals Congratulates our Scientific Advisory Board Member, Drew Weissman, M.D., Ph.D., for Receiving the Nobel Prize in Physiology or Medicine for his Pioneering Work Enabling the Development of mRNA COVID-19 Vaccines

FORT WORTH, Texas, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on...

TFF Pharmaceuticals to Participate in Upcoming Investor Conferences

FORT WORTH, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on...

TFF Pharmaceuticals to Participate in the H.C. Wainwright 25th Annual Global Investment Conference – September 11-13, 2023

FORT WORTH, Texas, Aug. 23, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on...

TFF Pharmaceuticals Announces Closing of $5.7 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option

FORT WORTH, Texas, Aug. 17, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (the “Company”), a clinical-stage biopharmaceutical...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Pre-market stock movers are a hot topic with investors this morning and we're checking out the biggest ones worth watching on Tuesday!

TFF Pharmaceuticals down 22%, prices $5M offering (NASDAQ:TFFP)

Clinical-stage biopharmaceutical company, TFF Pharmaceuticals (TFFP) stock price drooped 22%, priced its underwritten public offering of 19,896,000 shares at a public offering price...